Company Coeptis Therapeutics Holdings, Inc.

COEP

US19207A1088

Pharmaceuticals

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:00:00 11/05/2024 am IST			5-day change	1st Jan Change
0.3832 ^USD	+4.70%		+6.44%	-51.12%

26/03	Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
26/02	Coeptis Therapeutics Holdings, Inc. Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK	CI

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc. and Coeptis Pharmaceuticals, LLC., is a biopharmaceutical company. The Company owns, acquires, and develops cell therapy technologies for cancer and other diseases. Its product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen chimeric antigen receptor (CAR) T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which the Company is developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its CAR therapy is a treatment for cancer in which a patient's T cells are genetically engineered to recognize cancer cells to target and destroy them.

Number of employees: 6

Managers	Title	Age	Since
David Mehalick CEO	Chief Executive Officer	56	28/22/28
Brian Cogley DFI	Director of Finance/CFO	38	17/23/17
Daniel Yerace COO	Chief Operating Officer	41	28/22/28
Colleen Delaney CTO	Chief Tech/Sci/R&D Officer	57	30/23/30
Christine Sheehy CMP	Compliance Officer	57	28/22/28

Members of the board	Title	Age	Since
Philippe Deschamps BRD	Director/Board Member	62	28/22/28
Christopher Cochran BRD	Director/Board Member	55	28/22/28
Christine Sheehy CMP	Compliance Officer	57	28/22/28
Gene Salkind BRD	Director/Board Member	71	28/22/28
Chris Calise BRD	Director/Board Member	51	28/22/28
David Mehalick CEO	Chief Executive Officer	56	28/22/28
Daniel Yerace COO	Chief Operating Officer	41	28/22/28
Tara Maria DeSilva BRD	Director/Board Member	56	28/22/28

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	36,089,917	24,345,215 ( 67.46 %)	0	67.46 %

Name	Equities	%	Valuation
Armistice Capital LLC 9.753 %	3,520,000	9.753 %	1 M $
David Mehalick 7.208 %	2,601,311	7.208 %	772 589 $
Biofin Ventures LLC 6.650 %	2,400,000	6.650 %	712 800 $
Bull Horn Holdings Sponsor LLC 5.227 %	1,886,582	5.227 %	560 315 $
Christine Sheehy 2.800 %	1,010,605	2.800 %	300 150 $
Daniel Yerace 2.800 %	1,010,605	2.800 %	300 150 $
Creative Planning LLC 1.787 %	645,104	1.787 %	191 596 $
Chris Calise 1.396 %	503,698	1.396 %	149 598 $
Geode Capital Management LLC 0.5088 %	183,631	0.5088 %	54 538 $
Vanguard Group, Inc. (Subfiler) 0.3012 %	108,709	0.3012 %	32 287 $

Name	Equities	%	Valuation
Ionic Capital Management LLC -	518,728	-	12 968 $
RiverNorth Capital Management LLC -	150,000	-	3 750 $
Meteora Capital LLC -	148,443	-	3 711 $
Walleye Capital LLC -	109,050	-	2 726 $
Cantor Fitzgerald & Co. -	106,459	-	2 661 $
HRT Financial LLC -	100,115	-	2 503 $
Walleye Trading LLC -	72,560	-	1 814 $
SkyView Investment Advisors LLC -	55,122	-	1 378 $
Cowen & Co. LLC -	45,500	-	1 138 $
CSS LLC -	38,848	-	971 $

Coeptis Therapeutics Holdings, Inc.

105 Bradford Road Suite 420

15090, Wexford

http://www.coeptistx.com

address Coeptis Therapeutics Holdings, Inc.(COEP)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3832

Average target price

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
COEPTIS THERAPEUTICS HOLDINGS, INC.	-51.12%	13.83M
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals